Tycoon2FA has become a leading phishing-as-a-service (PhaaS) platforms, enabling campaigns that reach over 500,000 ...
Qure’s AMT-130 faces FDA efficacy doubts after 12-month data. QURE's upside now hinges on political pressure. Read here for ...
Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation ...
An informational industry analysis examining ingredient-level research, marketing positioning trends, regulatory context, and ...
Jay Olson Oppenheimer & Co. Inc., Research Division. Hello, everyone, and welcome to Oppenheimer's 36th Annual Life Science Conference. I'm Jay Olson, one of the biotech analysts ...
Dementia is one of the most feared conditions of old age because it slowly takes away memory, thinking ability, and independence. It affects millions of older adults worldwide and places a heavy ...
Non-inferiority trials are a valuable type of clinical trial to evaluate new treatments that might have differing benefits. Such trials are increasingly used, but have methodological challenges in ...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature handheld robotics and digital solutions ...
A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
The drug was finally approved in September 2025 through the FDA’s accelerated approval pathway, based on improvement in knee extensor muscle strength, for adults and children with Barth syndrome who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results